ROLE OF DORSAL HIPPOCAMPAL CANNABINOID RECEPTORS AND NITRIC OXIDE IN ANXIETY LIKE BEHAVIOURS IN RATS USING THE ELEVATED PLUS‐MAZE TEST

@article{Roohbakhsh2007ROLEOD,
  title={ROLE OF DORSAL HIPPOCAMPAL CANNABINOID RECEPTORS AND NITRIC OXIDE IN ANXIETY LIKE BEHAVIOURS IN RATS USING THE ELEVATED PLUS‐MAZE TEST},
  author={Ali Roohbakhsh and Akbar Hajizadeh Moghaddam and Roohollah Massoudi and Mohammad Reza Zarrindast},
  journal={Clinical and Experimental Pharmacology and Physiology},
  year={2007},
  volume={34}
}
1 The important role of the cannabinoid system in the modulation of anxiety like behaviours in clinical and experimental studies has been proposed. However, investigations into this effect of cannabinoids has produced contradictory results. It has been reported that different neurotransmitters, such as nitric oxide (NO), are involved in the behavioural effects of cannabinoids. The hippocampus is also an important brain region in the modulation of anxiety in which CB1 receptors are densely… 
View on Wiley
mbfys.ru.nl
72 Citations
Highly Influential Citations
6
Background Citations
30
Methods Citations
5
Results Citations
7

72 Citations

Cannabinoid system of the lateral septum in the modulation of anxiety-like behaviors in rats.

The results suggest that the cannabinoid system of the lateral septum modulates anxiety-like behavior through CB1 receptor in rats using elevated plus maze test.

Influence of nitric oxide agents in the dorsal hippocampus of mice on anxiogenic-like effect induced by histamine

Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect

Data indicate that activation of CB1 receptors in the dentate gyrus of the hippocampus results in an antidepressant-like response, highlighting the potential importance of changes in the hippocampal endocannabinoid system following stress or antidepressant treatment with respect to the manifestation and/or treatment of depression.

Role of endocannabinoid system in the ventral hippocampus of rats in the modulation of anxiety-like behaviours.

The results showed that injection of URB597 into the ventral hippocampus may be anxiogenic and GABAergic system may not be involved in its anxietyiogenic-like effects.

Interaction of GABA (A) system in the nucleus accumbens ahell with ACPA on anxiety-like behaviors in Wistar male rat

The results suggested that the activation of the NAc shell GABA (A) receptor attenuated the activity of cannabinoid system in theNAc shell.

Cannabinoid CB1 receptors in the dorsal hippocampus and prelimbic medial prefrontal cortex modulate anxiety-like behavior in rats: Additional evidence

Interaction between mecamylamine and nitric oxide in dorsal hippocampus using the elevated plus-maze test of anxiety

Results reveal that both nitric oxide and mecamylamine not only play a part in the modulation of anxiety in the dorsal hippocampus of mouse but also have demonstrated a complex interaction as well.

The cannabinoid CB1 receptor is involved in the anxiolytic, sedative and amnesic actions of benzodiazepines

Findings revealed that cannabinoid CB1 receptor plays a pivotal role in the pharmacological actions of benzodiazepines and suggests that blockade of cannabinoids CB1 receptors may be useful in the treatment of patients with problems related to the consumption of benzidiazepines.

Dorsal hippocampus cannabinoid type 1 receptors modulate the expression of contextual fear conditioning in rats: Involvement of local glutamatergic/nitrergic and GABAergic neurotransmissions

Influence of nitric oxide agents in the rat amygdala on anxiogenic-like effect induced by histamine

...

References

SHOWING 1-10 OF 46 REFERENCES

CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents

The studies on the behavioural effects of the cannabinoid antagonist SR-141716A and theCB1 antagonist AM-251 show that the CB1 and the novel cannabinoid receptor mediate anxiolytic and anxiogenic effects, respectively, which suggests that agonists of the former, or antagonists of the latter, are promising new compounds in the pharmacotherapy of anxiety.

Endocannabinoid system and stress and anxiety responses

Cholecystokinin and GABA interaction in the dorsal hippocampus of rats in the elevated plus-maze test of anxiety

The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain

Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters

The Role of the Dorsal Hippocampal Serotonergic and Cholinergic Systems in the Modulation of Anxiety

The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety

Findings suggest that the discrepancy between the effects of the genetic and pharmacological blockade of the CB1 receptor suggests that the novel receptor plays a role in anxiety, as the cannabinoid receptor antagonist affected anxiety in both wild type and CB1‐knockout mice.

Neurobehavioral Effects of Anandamide and Cannabinoid Receptor Gene Expression in Mice

‘One‐trial sensitization’ to the anxiolytic‐like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus‐maze

The apparent experientially induced ‘sensitization’ to the anxiolytic‐like effects of SR141716A in the plus‐maze contrasts markedly with the widely reported loss of benzodiazepine efficacy in test‐experienced animals.

Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice

The cholinergic axon terminals of the NMRI mouse hippocampus are endowed with presynaptic CB1 receptors, and the maximum extent of the CB1 receptor-mediated inhibition of acetylcholine release is lower than the maximum effect mediated via the autoreceptor.